ClinicalTrials.Veeva

Menu

Comparing the Efficiency of Three Third-generation Supraglottic Airways as an Intubation Route

U

Université de Sherbrooke

Status

Completed

Conditions

Difficult Intubation

Treatments

Device: Insertion of I-Gel and intubation through the device
Device: Insertion of AuraGain and intubation through the device
Device: Insertion of AirQ Blocker and intubation through the device

Study type

Interventional

Funder types

Other

Identifiers

NCT02975466
2017-1484

Details and patient eligibility

About

A "can't intubate, can't oxygenate" situation is life-threatening and the physician must be prepared to react quickly. Similarly, a difficult intubation with adequate ventilation is associated with complications. In both of these situation and as recommend by different societies, a supra-glottic airway (SGA) device can be used to help ventilation, or as an intubation conduit to ease the airway access. The objective of this randomized controlled trial is to establish which SGA, between the AuraGain, AirQ Blocker and I-Gel, allows the fastest intubation time in an adult population, with the objective of minimizing complications related to these situations. The investigators will conduct a three-arm trial to compare different outcomes related to the installation of the SGA and its use as an intubation conduit. The results of this trial will inform the anesthesiologist on which device to use on to have close in case of airway emergencies.

Enrollment

150 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age >18 years old
  • ASA score of 1-3
  • Elective or urgent surgery planned to last at least 30 minutes under general anesthesia with endotracheal intubation

Exclusion criteria

  • Any contraindication to the use of SGA devices considered by the anesthesiologist (Uncontrolled gastro-eosophageal reflux, oropharyngeal pathology or gross deformation, etc.)
  • Any contraindication to the drugs planned by the trial
  • Pregnancy
  • Severe or uncontrolled obstructive pulmonary disease
  • Significant cervical spine anomaly

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

150 participants in 3 patient groups

AirQ Blocker supra-glottic airway device
Experimental group
Description:
Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
Treatment:
Device: Insertion of AirQ Blocker and intubation through the device
AuraGain supra-glottic airway device
Experimental group
Description:
Group of patients in which the AuraGain will be used and measured as an intubation conduit.
Treatment:
Device: Insertion of AuraGain and intubation through the device
I-Gel supra-glottic airway device
Experimental group
Description:
Group of patients in which the I-Gel will be used and measured as an intubation conduit.
Treatment:
Device: Insertion of I-Gel and intubation through the device

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems